IO Biotech Valuation
| IOBT Stock | USD 0.75 0.04 5.63% |
IO Biotech is undervalued. IO Biotech owns a latest Real Value of $3.06 per share. The recent price of the firm is $0.75. Our model calculates the value of IO Biotech from inspecting the firm fundamentals such as Return On Asset of -0.51, ebitda of (91.23 M), and Shares Outstanding of 65.88 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting IO Biotech's valuation include:
Price Book 0.6809 | Enterprise Value -28.8 M | Enterprise Value Ebitda 1.3637 |
Undervalued
Today
Please note that IO Biotech's price fluctuation is dangerous at this time. Calculation of the real value of IO Biotech is based on 3 months time horizon. Increasing IO Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
IO Biotech's intrinsic value may or may not be the same as its current market price of 0.75, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.75 | Real 3.06 | Target 10.0 | Hype 0.77 |
The intrinsic value of IO Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence IO Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of IO Biotech helps investors to forecast how IOBT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IO Biotech more accurately as focusing exclusively on IO Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use IO Biotech's intrinsic value based on its ongoing forecasts of IO Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against IO Biotech's closest peers.
IO Biotech Cash |
|
IOBT Valuation Trend
IO Biotech's real value is important for investors to make better decisions and a more accurate overall view of IO Biotech's financial worth over time. Using both IO Biotech's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
IO Biotech Total Value Analysis
IO Biotech is currently forecasted to have valuation of (28.76 M) with market capitalization of 49.41 M, debt of 2.49 M, and cash on hands of 170.12 M. The negative valuation of IO Biotech may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the IO Biotech fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(28.76 M) | 49.41 M | 2.49 M | 170.12 M |
IO Biotech Asset Utilization
One of the ways to look at asset utilization of IOBT is to check how much profit was generated for every dollar of assets it reports. IO Biotech owns a negative utilization of current and long term assets of -0.51 %, losing $0.005098 for each dollar of current and long term assets held by the firm. Discouraging asset utilization attests that the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of IO Biotech shows how wasteful it operates for each dollar spent on its current and long term assets.IO Biotech Ownership Allocation
IO Biotech secures a total of 65.88 Million outstanding shares. The majority of IO Biotech outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to purchase positions in IO Biotech to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in IO Biotech. Please pay attention to any change in the institutional holdings of IO Biotech as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.IO Biotech Profitability Analysis
Net Loss for the year was (86.08 M) with profit before overhead, payroll, taxes, and interest of 0.About IO Biotech Valuation
The stock valuation mechanism determines IO Biotech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of IO Biotech based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of IO Biotech. We calculate exposure to IO Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IO Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -756 K | -793.8 K |
IO Biotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as IO Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 43.5 M |
IO Biotech Current Valuation Indicators
IO Biotech's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final IO Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as IO Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use IO Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes IO Biotech's worth.Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.